Published

Psychedelic drugs-a new era in psychiatry?.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Dialogues in clinical neuroscience
Date: 2019-01-01
Source: PubMed
DOI: 10.31887/dcns.2019.21.2/dnutt
PubMed: 31636488

Authors

Nutt D

Watch author

Derived topics and classifications

psilocybin Depression Anxiety PTSD Addiction OCD Clinical Trial Treatment-Resistant Depression Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 5 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

The astrocytes in the prefrontal cortex contribute to the rapid antidepressant-like effects of psilocybin in the chronic restraint stress mouse model2026-04-01 Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention2026-03-01 Elucidating the Phase I metabolism of psilocin in vitro2025-03-01 Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans2021-03-15 Psychedelic drugs-a new era in psychiatry?.2019-01-01

Related papers

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04